Tumor Lysis Syndrome News and Research

RSS
Pronai Therapeutics reports positive results from PNT2258 Phase II study on lymphoma

Pronai Therapeutics reports positive results from PNT2258 Phase II study on lymphoma

ARIAD temporarily suspends commercial distribution of Iclusig drug in US

ARIAD temporarily suspends commercial distribution of Iclusig drug in US

FDA grants accelerated approval for Kyprolis to treat multiple myeloma

FDA grants accelerated approval for Kyprolis to treat multiple myeloma

FDA grants accelerated approval to Onyx's Kyprolis for treatment of multiple myeloma

FDA grants accelerated approval to Onyx's Kyprolis for treatment of multiple myeloma

Celgene reports final results from REVLIMID-rituximab combination phase II study for relapsed/refractory CLL

Celgene reports final results from REVLIMID-rituximab combination phase II study for relapsed/refractory CLL

Celgene announces interim results of REVLIMID study on CLL

Celgene announces interim results of REVLIMID study on CLL

Gene therapy to combat leukemia

Gene therapy to combat leukemia

Gleevec shows significant overall survival benefit for patients w/ GIST after 3 years of adjuvant treatment vs. 1 year

Gleevec shows significant overall survival benefit for patients w/ GIST after 3 years of adjuvant treatment vs. 1 year

3SBio acquires pegsiticase global rights from EnzymeRx for $6.25 million

3SBio acquires pegsiticase global rights from EnzymeRx for $6.25 million

Experts address fundamental questions related to renal failure in ICU

Experts address fundamental questions related to renal failure in ICU

EnzymeRx reports positive results from first clinical trial of pegsitacase for refractory gout

EnzymeRx reports positive results from first clinical trial of pegsitacase for refractory gout

Enzymerx completes enrollment for clinical trial of pegsitacase

Enzymerx completes enrollment for clinical trial of pegsitacase

Rituxan, intended for patients with CLL receives FDA approval

Rituxan, intended for patients with CLL receives FDA approval

Data evaluating combination therapy with REVLIMID and rituximab in patients with NHL presented

Data evaluating combination therapy with REVLIMID and rituximab in patients with NHL presented

Positive data from Gloucester Pharmaceuticals' ISTODAX study presented at the ASH meeting

Positive data from Gloucester Pharmaceuticals' ISTODAX study presented at the ASH meeting

EnzymeRx commences patient enrollment in Uricase-PEG 20 phase 1 study

EnzymeRx commences patient enrollment in Uricase-PEG 20 phase 1 study

FDA grants marketing approval for Elitek

FDA grants marketing approval for Elitek

Investigational New Drug application for Uricase-PEG 20 approved

Investigational New Drug application for Uricase-PEG 20 approved

Genentech and Biogen Idec submit applications to FDA for Rituxan in chronic lymphocytic leukemia

Genentech and Biogen Idec submit applications to FDA for Rituxan in chronic lymphocytic leukemia

Study of Rituxan (rituximab) in lupus nephritis misses primary endpoint

Study of Rituxan (rituximab) in lupus nephritis misses primary endpoint

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.